Netherton syndrome: Defective kallikrein inhibition in the skin leads to skin inflammation and allergy

Biological Chemistry

Volumn 395, Issue 9, 2014, Pages 945-958

  Furio, Laetitia ^a,b   Hovnanian, Alain ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b IMAGINE INSTITUTE   (France)

^c Department of Genetics ^*  (France)

Author keywords

Allergy; Kallikrein; Netherton syndrome; Skin inflammation

Indexed keywords

ADALIMUMAB; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGOBULIN LIKE 1; ANTIBIOTIC AGENT; EMOLLIENT AGENT; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HISTAMINE H1 RECEPTOR ANTAGONIST; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 8; KALLIKREIN; KALLIKREIN 14; KALLIKREIN 5; KALLIKREIN INHIBITOR; LEKTI 1; LEKTI 2; PIMECROLIMUS; POLYPEPTIDE ANTIBIOTIC AGENT; PROFILAGGRIN; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SPINK6; STEROID; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TACROLIMUS; TRYPSIN; ULINASTATIN; UNCLASSIFIED DRUG;

ALLERGY; CLINICAL FEATURE; CONFERENCE PAPER; DERMATITIS; ENZYME INHIBITION; ENZYME REGULATION; FAILURE TO THRIVE; HAIR FOLLICLE; HUMAN; HYPEREOSINOPHILIA; NETHERTON DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT STATURE; SKIN; STRATUM CORNEUM; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ENZYMOLOGY; HYPERSENSITIVITY; INFLAMMATION; METABOLISM; NETHERTON SYNDROME; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY; INFLAMMATION; KALLIKREINS; NETHERTON SYNDROME; SKIN;

EID: 84908111732     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0137     Document Type: Conference Paper

References (116)

1. Alef, T., Torres, S., Hausser, I., Metze, D., Tursen, U., Lestringant, G.G., and Hennies, H.C. (2009). Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J. Invest. Dermatol. 129, 862-869.
2. Allen, A., Siegfried, E., Silverman, R., Williams, M.L., Elias, P.M., Szabo, S.K., and Korman, N.J. (2001). Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 137, 747-750.
3. Basel-Vanagaite, L., Attia, R., Ishida-Yamamoto, A., Rainshtein, L., Ben Amitai, D., Lurie, R., Pasmanik-Chor, M., Indelman, M., Zvulunov, A., Saban, S., et al., (2007). Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, E., encoding type II transmembrane serine protease matriptase. Am. J. Hum. Genet. 80, 467-477.
4. Beljan, G., Traupe, H., Metze D., and Sunderkotter, C. (2003). [Comel-Netherton syndrome with bacterial superinfection]. Hautarzt 54, 1198-1202.
5. Bennett, K., Callard, R., Heywood, W., Harper, J., Jayakumar, A., Clayman, G.L., Di, W.L., and Mills, K. (2010). New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. J. Proteome Res. 9, 4289-4294.
6. Bennett, K., Heywood, W., Di, W.L., Harper, J., Clayman, G.L., Jayakumar, A., Callard R., and Mills, K. (2012). The identification of a new role for LEKTI in the skin: the use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome. J. Proteomics 75, 3925-3937.
7. Bens, G., Boralevi, F., Buzenet C., and Taieb, A. (2003). Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. Br. J. Dermatol. 149, 224-226.
8. Bitoun, E., Micheloni, A., Lamant, L., Bonnart, C., Tartaglia-Polcini, A., Cobbold, C., Al Saati, T., Mariotti, F., Mazereeuw-Hautier, J., Boralevi, F., et al., (2003). LEKTI proteolytic processing in human primary keratinocytes, M., tissue distribution and defective expression in Netherton syndrome. Hum. Mol. Genet. 12, 2417-2430.
9. Bonnart, C., Deraison, C., Lacroix, M., Uchida, Y., Besson, C., Robin, A., Briot, A., Gonthier, M., Lamant, L., Dubus, P., et al. (2010). Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest. 120, 871-882.
10. Borgoño, A.C., Michael, I.P., Komatsu, N., Jayakumar, A., Kapadia, R., Clayman, G.L., Sotiropoulou, G., and Diamandis, E.P. (2007). A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282, 3640-3652.
11. Brattsand, M., Stefansson, K., Lundh, C., Haasum, Y., and Egelrud, T. (2005). A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124, 198-203.
12. Brattsand, M., Stefansson, K., Hubiche, T., Nilsson S.K., and Egelrud, T. (2009). SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor. J. Invest. Dermatol. 129, 1656-1665.
13. Briot, A., Deraison, C., Lacroix, M., Bonnart, C., Robin, A., Besson, C., Dubus, P., and Hovnanian, A. (2009). Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 206, 1135-1147.
14. Briot, A., Lacroix, M., Robin, A., Steinhoff, M., Deraison, C., and Hovnanian, A. (2010). Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J. Invest. Dermatol. 130, 2736-2742.
15. Buddenkotte, J., Stroh, C., Engels, I.H., Moormann, C., Shpacovitch, V.M., Seeliger, S., Vergnolle, N., Vestweber, D., Luger, T.A., Schulze-Osthoff, K., et al. (2005). Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-κB. J. Invest. Dermatol. 124, 38-45.
16. Candi, E., Schmidt, R., and Melino, G. (2005). The cornified envelope: a model of cell death in the skin. Nat. Rev. Mol. Cell. Biol. 6, 328-340.
17. Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M., and Serre, G. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122, 1235-1244.
18. Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A.D., Bonafe, J.L., Wilkinson, J., Taieb, A., Barrandon, Y., et al., (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25, 141-142.
19. Comel, M. (1949). Ichthyosis Linearis circumflexa. Dermatologica 98, 133-136.
20. Dale, A.B., Resing, K.A., and Lonsdale-Eccles, J.D. (1985). Filaggrin: a keratin filament associated protein. Ann. NY Acad. Sci. 455, 330-342.
21. De, Y., Chen, Q., Schmidt, A.P., Anderson, G.M., Wang, J.M., Wooters, J., Oppenheim, J.J., and Chertov, O. (2000). LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069-1074.
22. Denecker, G., Hoste, E., Gilbert, B., Hochepied, T., Ovaere, P., Lippens, S., Van den Broecke, C., Van Damme, P., D'Herde, K., Hachem, J.P., et al., (2007). Caspase-14 protects against epidermal UVB photodamage and water loss. Nat. Cell. Biol. 9, 666-674.
23. Denecker, G., Ovaere, P., Vandenabeele, P., and Declercq, W. (2008). Caspase-14 reveals its secrets. J. Cell Biol. 180, 451-458.
24. Deraison, C., Bonnart, C., Lopez, F., Besson, C., Robinson, R., Jayakumar, A., Wagberg, F., Brattsand, M., Hachem, J.P., Leonardsson, G., et al. (2007). LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 18, 3607-3619.
25. Descargues, P., Deraison, C., Bonnart, C., Kreft, M., Kishibe, M., Ishida-Yamamoto, A., Elias, P., Barrandon, Y., Zambruno, G., Sonnenberg, A., et al., (2005). Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 37, 56-65.
26. Descargues, P., Deraison, C., Prost, C., Fraitag, S., Mazereeuw-Hautier, J., D'Alessio, M., Ishida-Yamamoto, A., Bodemer, C., Zambruno, G., and Hovnanian, A. (2006). Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol. 126, 1622-1632.
27. Di, L.W., Larcher, F., Semenova, E., Talbot, G.E., Harper, J.I., Del Rio, M., Thrasher, A.J., and Qasim, W. (2011). Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 19, 408-416.
28. Di, L.W., Mellerio, J.E., Bernadis, C., Harper, J., Abdul-Wahab, A., Ghani, S., Chan, L., Martinez-Queipo, M., Hara, H., McNicol, A.M., et al., (2013). Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum. Gene. Ther. Clin. Dev. 24, 182-190.
29. Egelrud, T., Brattsand, M., Kreutzmann, P., Walden, M., Vitzithum, K., Marx, U.C., Forssmann, W.G., and Magert, H.J. (2005). hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br. J. Dermatol. 153, 1200-1203.
30. Eissa, A. and Diamandis, E.P. (2011). Kallikrein protease involvement in skin pathologies supports a new view of the origin of inflamed itchy skin. In: Proteases and Their Receptors in Inflammation. N. Vergnolle and M. Chignard, eds. (Basel, Switzerland: Springer), pp. 51-71.
31. Elias, M.P., Hatano, Y., and Williams, M.L. (2008). Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J. Allergy Clin. Immunol. 121, 1337-1343.
32. Fartasch, M., Williams, M.L., and Elias, P.M. (1999). Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch. Dermatol. 135, 823-832.
33. Folster-Holst, R., Swensson, O., Stockfleth, E., Monig, H., Mrowietz, U., and Christophers, E. (1999). Comel-Netherton syndrome complicated by papillomatous skin lesions containing human papillomaviruses 51 and 52 and plane warts containing human papillomavirus 16. Br. J. Dermatol. 140, 1139-1143.
34. Fontao, L., Laffitte, E., Briot, A., Kaya, G., Roux-Lombard, P., Fraitag, S., Hovnanian A.A., and Saurat, J.H. (2011). Infliximab infusions for netherton Syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J. Invest. Dermatol. 131, 1947-1950.
35. Fortugno, P., Bresciani, A., Paolini, C., Pazzagli, C., El Hachem, M., D'Alessio, M., and Zambruno, G. (2011). Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J. Invest. Dermatol. 131, 2223-2232.
36. Fuchs, E. and Raghavan, S. (2002). Getting under the skin of epidermal morphogenesis. Nat. Rev. Genet. 3, 199-209.
37. Furio, L. and Hovnanian, A. (2011). When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition. J. Invest. Dermatol. 131, 2169-2173.
38. Furio, L., de Veer, S., Jaillet, M., Briot, A., Robin, A., Deraison, C., and Hovnanian, A. (2014). Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J. Exp. Med. 211, 499-513.
39. Galliano, F.M., Toulza, E., Gallinaro, H., Jonca, N., Ishida-Yamamoto, A., Serre, G., and Guerrin, M. (2006). A novel protease inhibitor of the alpha2-macroglobulin family expressed in the human epidermis. J. Biol. Chem. 281, 5780-5789.
40. Giroux, D.J., Sizun, J., Gardach, C., Awad, H., Guillois, B., and Alix, D. (1993). Severe hypernatremic dehydration disclosing Netherton syndrome in the neonatal period. Arch. Fr. Pediatr. 50, 585-588.
41. Godic, A. and Dragos, V. (2004). Successful treatment of Netherton's syndrome with topical calcipotriol. Eur. J. Dermatol. 14, 115-117.
42. Guma, M., Ronacher, L., Liu-Bryan, R., Takai, S., Karin, M., and Corr, M. (2009). Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 60, 3642-3650.
43. Hachem, P.J., Wagberg, F., Schmuth, M., Crumrine, D., Lissens, W., Jayakumar, A., Houben, E., Mauro, T.M., Leonardsson, G., Brattsand, M., et al. (2006). Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol. 126, 1609-1621.
44. Hansson, L., Backman, A., Ny, A., Edlund, M., Ekholm, E., Ekstrand Hammarstrom, B., Tornell, J., Wallbrandt, P., Wennbo, H., and Egelrud, T. (2002). Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 118, 444-449.
45. Hatano, Y., Terashi, H., Arakawa, S., and Katagiri, K. (2005). Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J. Invest. Dermatol. 124, 786-792.
46. Hausser, I. and Anton-Lamprecht, I. (1996). Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr. Dermatol. 13, 183-199.
47. Heinz-Erian, P., Muller, T., Krabichler, B., Schranz, M., Becker, C., Ruschendorf, F., Nurnberg, P., Rossier, B., Vujic, M., Booth, I.W., et al., (2009). Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am. J. Hum. Genet. 84, 188-196.
48. Hewett, R.D., Simons, A.L., Mangan, N.E., Jolin, H.E., Green, S.M., Fallon, P.G., and McKenzie, A.N. (2005). Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Hum. Mol. Genet. 14, 335-346.
49. Hintner, H., Jaschke, E., and Fritsch, P. (1980). Netherton syndrome: weakened immunity, generalized verrucosis and carcinogenesis. Hautarzt 31, 428-432.
50. Hosomi, N., Fukai, K., Nakanishi, T., Funaki, S., and Ishii, M. (2008). Caspase-1 activity of stratum corneum and serum interleukin-18 level are increased in patients with Netherton syndrome. Br. J. Dermatol. 159, 744-746.
51. Hou, L., Kapas, S., Cruchley, A.T., Macey, M.G., Harriott, P., Chinni, C., Stone, S.R., and Howells, G.L. (1998). Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology 94, 356-362.
52. Hovnanian, A. (2012). Netherton syndrome: new advances in clinic, disease mechanism and treatment. Expert Review 7, 81-92.
53. Hovnanian, A. (2013). Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 351, 289-300.
54. Ishida-Yamamoto, A., Deraison, C., Bonnart, C., Bitoun, E., Robinson, R., O'Brien, T.J., Wakamatsu, K., Ohtsubo, S., Takahashi, H., Hashimoto, Y., et al. (2005). LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J. Invest. Dermatol. 124, 360-366.
55. Jayakumar, A., Kang, Y., Mitsudo, K., Henderson, Y., Frederick, M.J., Wang, M., El-Naggar, A.K., Marx, U.C., Briggs, K., and Clayman, G.L. (2004). Expression of LEKTI domains 6-9′ in the baculovirus expression system: recombinant LEKTI domains 6-9′ inhibit trypsin and subtilisin A. Protein Expr. Purif. 35, 93-101.
56. Judge, R.M., Morgan, G., and Harper, J.I. (1994). A clinical and immunological study of Netherton's syndrome. Br. J. Dermatol. 131, 615-621.
57. Komatsu, N., Saijoh, K., Toyama, T., Ohka, R., Otsuki, N., Hussack, G., Takehara, K., and Diamandis, E.P. (2005). Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br. J. Dermatol. 153, 274-281.
58. Komatsu, N., Saijoh, K., Otsuki, N., Kishi, T., Micheal, I.P., Obiezu, C.V., Borgono, C.A., Takehara, K., Jayakumar, A., Wu, H.K., et al., (2007). Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. Clin. Chim. Acta 377, 228-236.
59. Krasagakis, K., Ioannidou, D.J., Stephanidou, M., Manios, A., Panayiotides, J.G., and Tosca, A.D. (2003). Early development of multiple epithelial neoplasms in Netherton syndrome. Dermatology 207, 182-184.
60. Kreutzmann, P., Schulz, A., Standker, L., Forssmann, W.G., and Magert, H.J. (2004). Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 803, 75-81.
61. Leyvraz, C., Charles, R.P., Rubera, I., Guitard, M., Rotman, S., Breiden, B., Sandhoff, K., and Hummler, E. (2005). The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J. Cell Biol. 170, 487-496.
62. Li, L.A., Walsh, S., and McKay, D.R. (2011). Surgical management of a giant condyloma of Buschke-Lowenstein in a patient with Netherton syndrome using the pedicled anterolateral thigh flap-a case report. J. Plast. Reconstr. Aesthet. Surg. 64, 1533-1536.
63. List, K., Szabo, R., Wertz, P.W., Segre, J., Haudenschild, C.C., Kim, S.Y., and Bugge, T.H. (2003). Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 163, 901-910.
64. Matsui, T., Miyamoto, K., Kubo, A., Kawasaki, H., Ebihara, T., Hata, K., Tanahashi, S., Ichinose, S., Imoto, I., Inazawa, J., et al., (2011). SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol. Med. 3, 320-333.
65. Mazereeuw-Hautier, J., Cope, J., Ong, C., Green, A., Hovnanian, A., and Harper, J.I. (2006). Topical recombinant alpha1-antitrypsin: a potential treatment for Netherton syndrome? Arch. Dermatol. 142, 396-398.
66. Meyer-Hoffert, U., Wu, Z., and Schroder, J.M. (2009). Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS One 4, e4372.
67. Meyer-Hoffert, U., Wu, Z., Kantyka, T., Fischer, J., Latendorf, T., Hansmann, B., Bartels, J., He, Y., Glaser, R., and Schroder, J.M. (2010). Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J. Biol. Chem. 285, 32174-32181.
68. Mitsudo, K., Jayakumar, A., Henderson, Y., Frederick, M.J., Kang, Y., Wang, M., El-Naggar, A.K., and Clayman, G.L. (2003). Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 42, 3874-3881.
69. Miyai, M., Matsumoto, Y., Yamanishi, H., Yamamoto-Tanaka, M., Tsuboi, R., and Hibino, T. (2014). Keratinocyte-Specific Mesotrypsin Contributes to the Desquamation Process via Kallikrein Activation and LEKTI Degradation. J Invest Dermatol. 134, 1665-1674.
70. Mizutani, R.H., Schechter, N., Lazarus, G., Black, R.A., and Kupper, T.S. (1991). Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174, 821-825.
71. Nagaike, K., Kawaguchi, M., Takeda, N., Fukushima, T., Sawaguchi, A., Kohama, K., Setoyama, M., and Kataoka, H. (2008). Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice. Am. J. Pathol. 173, 1464-1475.
72. Natsuga, K., Akiyama, M., and Shimizu, H. (2011). Malignant skin tumours in patients with inherited ichthyosis. Br. J. Dermatol. 165, 263-268.
73. Netherton, E.W. (1958). A unique case of trichorrhexis nodosa: bamboo hairs. AMA Arch. Derm 78, 483-487.
74. Niyonsaba, F., Ushio, H., Hara, M., Yokoi, H., Tominaga, M., Takamori, K., Kajiwara, N., Saito, H., Nagaoka, I., Ogawa, H., et al., (2010). Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J. Immunol. 184, 3526-3534.
75. Ny, A. and Egelrud, T. (2003). Transgenic mice over-expressing a serine protease in the skin: evidence of interferon gamma-independent MHC II expression by epidermal keratinocytes. Acta Derm. Venereol. 83, 322-327.
76. Ny, A. and Egelrud, T. (2004). Epidermal hyperproliferation and decreased skin barrier function in mice overexpressing stratum corneum chymotryptic enzyme. Acta Derm. Venereol. 84, 18-22.
77. Nylander-Lundqvist, E. and Egelrud, T. (1997). Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm. Venereol. 77, 203-206.
78. Ohler, A., Debela, M., Wagner, S., Magdolen, V., and Becker-Pauly, C. (2010). Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol. Chem. 391, 455-460.
79. Oji, V., Beljan, G., Beier, K., Traupe, H., and Luger, T.A. (2005). Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br. J. Dermatol. 153, 1067-1068.
80. Ong, A. and Harper, J. (2006). Netherton's syndrome. In: Textbook of Pediatric Dermatology. J. Harper, A. Oranje and N. Prose, eds. (Turin, Italy, Blackwell), pp. 1359-1366.
81. Pearton, J.D., Nirunsuksiri, W., Rehemtulla, A., Lewis, S.P., Presland, R.B., and Dale, B.A. (2001). Proprotein convertase expression and localization in epidermis: evidence for multiple roles and substrates. Exp. Dermatol. 10, 193-203.
82. Rattenholl, A. and Steinhoff, M. (2008). Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect. 21, 369-381.
83. Renner, D.E., Hartl, D., Rylaarsdam, S., Young, M.L., Monaco-Shawver, L., Kleiner, G., Markert, M.L., Stiehm, E.R., Belohradsky, B.H., Upton, M.P., et al. (2009). Comel-Netherton syndrome defined as primary immunodeficiency. J. Allergy Clin. Immunol. 124, 536-543.
84. Resing, A.K., Thulin, C., Whiting, K., al-Alawi, N., and Mostad, S. (1995). Characterization of profilaggrin endoproteinase 1. A regulated cytoplasmic endoproteinase of epidermis. J. Biol. Chem. 270, 28193-28198.
85. Roedl, D., Oji, V., Buters, J.T., Behrendt, H., and Braun-Falco, M. (2011). rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients. J. Dermatol. Sci. 61, 194-198.
86. Saghari, S., Woolery-Lloyd, H., and Nouri, K. (2002). Squamous cell carcinoma in a patient with Netherton's syndrome. Inter. J. Dermatol. 41, 415-416.
87. Saif, H.G.B. and Al-Khenaizan, S. (2007). Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int. J. Dermatol. 46, 290-294.
88. Sakabe, J., Yamamoto, M., Hirakawa, S., Motoyama, A., Ohta, I., Tatsuno, K., Ito, T., Kabashima, K., Hibino, T., and Tokura, Y. (2013). Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes. J. Biol. Chem. 288, 17179-17189.
89. Sales, U.K., Masedunskas, A., Bey, A.L., Rasmussen, A.L., Weigert, R., List, K., Szabo, R., Overbeek, P.A., and Bugge, T.H. (2010). Matriptase initiates activation of epidermal prokallikrein and disease onset in a mouse model of Netherton syndrome. Nat. Genet. 42, 676-683.
90. Sandilands, A., Sutherland, C., Irvine, A.D., and McLean, W.H. (2009). Filaggrin in the frontline: role in skin barrier function and disease. J. Cell Sci. 122, 1285-1294.
91. Schalkwijk, J., Chang, A., Janssen, P., De Jongh, G.J., and Mier, P.D. (1990). Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br. J. Dermatol. 122, 631-641.
92. Schechter, M.N., Choi, E.J., Wang, Z.M., Hanakawa, Y., Stanley, J.R., Kang, Y., Clayman, G.L. and Jayakumar, A. (2005). Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol. Chem. 386, 1173-1184.
93. Segre, J.A. (2006). Epidermal barrier formation and recovery in skin disorders. J. Clin. Invest. 116, 1150-1158.
94. Soumelis, V., Reche, P.A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002). Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3, 673-680.
95. Stehlik, C. (2009). Multiple interleukin-1beta-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum. 60, 3524-3530.
96. Steinhoff, M., Corvera, C.U., Thoma, M.S., Kong, W., McAlpine, B.E., Caughey, G.H., Ansel, J.C., and Bunnett, N.W. (1999). Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp. Dermatol. 8, 282-294.
97. Steinhoff, M., Neisius, U., Ikoma, A., Fartasch, M., Heyer, G., Skov, P.S., Luger, T.A., and Schmelz M. (2003). Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23, 6176-6180.
98. Stoll, C., Alembik, Y., Tchomakov, D., Messer, J., Heid, E., Boehm, N., Calvas, P., and Hovnanian, A. (2001). Severe hypernatremic dehydration in an infant with Netherton syndrome. Genet. Couns. 12, 237-243.
99. Stryk, S., Siegfried, E.C., and Knutsen, A.P. (1999). Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Pediatr. Dermatol. 16, 19-22.
100. Sun, J.D. and Linden, K.G. (2006). Netherton syndrome: a case report and review of the literature. Int J Dermatol. 45, 693-697.
101. Szabo, R., Kosa, P., List, K., and Bugge, T.H. (2009). Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Am. J. Pathol. 174, 2015-2022.
102. Takai, T. and Ikeda, S. (2011). Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol. Int. 60, 25-35.
103. Tartaglia-Polcini, A., Bonnart, C., Micheloni, A., Cianfarani, F., Andre, A., Zambruno, G., Hovnanian, A., and D'Alessio, M. (2006). SPINK5, the defective gene in netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing. J. Invest. Dermatol. 126, 315-324.
104. Traupe, H. (1989). The Comel-Netherton syndrome. The Ichthyoses. A Guide to Clinical Diagnosis, Genetic Counseling and Therapy. (Berlin, Germany: Springer-Verlag), pp. 168-178.
105. van der Voort, E.A. and Prens, E.P. (2013). Netherton syndrome with multiple non-melanoma skin cancers. Acta Derm. Venereol. 93, 727-728.
106. Van Gysel, D., Koning, H., Baert, M.R., Savelkoul, H.F., Neijens, H.J., and Oranje, A.P. (2001). Clinico-immunological heterogeneity in Comel-Netherton syndrome. Dermatology 202, 99-107.
107. Wakita, H., Furukawa, F., and Takigawa, M. (1997). Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes. Proc. Assoc. Am. Physicians 109, 190-207.
108. Weber, F., Fuchs, P.G., Pfister, H.J., Hinter, H., Fritsch, P., and Hoepfl, R. (2001). Human papillomavirus infection in Nehterton's syndrome. Br. J. Dermatol. 144, 1044-1049.
109. Wingens, P.M., van Bergen, B.H., Hiemstra, P.S., Meis, J.F., van Vlijmen-Willems, I.M., Zeeuwen, P.L., Mulder, J., Kramps, H.A., van Ruissen, F., and Schalkwijk, J. (1998). Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J. Invest. Dermatol. 111, 996-1002.
110. Witt, H., Luck, W., Hennies, H.C., Classen, M., Kage, A., Lass, U., Landt, O., and Becker, M. (2000). Mutations in the gene encoding the serine protease inhibitor Kazal type 1 are associated with chronic pancreatitis. Nat. Genet. 25, 213-216.
111. Yamasaki, K., Schauber, J., Coda, A., Lin, H., Dorschner, R.A., Schechter, N.M., Bonnart, C., Descargues, P., Hovnanian, A., and Gallo, R.L. (2006). Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. Faseb J. 20, 2068-2080.
112. Yamasaki, K., Kanada, K., Macleod, D.T., Borkowski, A.W., Morizane, S., Nakatsuji, T., Cogen, A.L., and Gallo, R.L. (2011). TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J. Invest. Dermatol. 131, 688-697.
113. Yamazaki, M., Ishidoh, K., Suga, Y., Saido, T.C., Kawashima, S., Suzuki, K., Kominami, E., and Ogawa, H. (1997). Cytoplasmic processing of human profilaggrin by active mu-calpain. Biochem. Biophys. Res. Commun. 235, 652-656.
114. Yan, C, A., Honig, P.J., Ming, M.E., Weber, J., and Shah, K.N. (2010). The safety and efficacy of pimecrolimus 1% cream for the treatment of Netherton syndrome: results from an exploratory study. Arch. Dermatol. 146, 57-62.
115. Yang, T., Liang, D., Koch, P.J., Hohl, D., Kheradmand, F., and Overbeek, P.A. (2004). Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in Spink5-/- mice. Genes Dev. 18, 2354-2358.
116. Yousef, M, G., Bharaj, B.S., Yu, H., Poulopoulos, J., and Diamandis, E.P. (2001). Sequence analysis of the human kallikrein gene locus identifies a unique polymorphic minisatellite element. Biochem. Biophys. Res. Commun. 285, 1321-1329.